

**MURAE ORGANISOR LIMITED**  
(Formerly known as Earum Pharmaceuticals Limited)

CIN: L24230GJ2012PLC071299

Regd. Office: A-1311, Sun West Bank, Ashram Road, Ahmedabad, Gujarat – 380 009

E-mail: [earumpharma@gmail.com](mailto:earumpharma@gmail.com) Website: [www.earumpharma.com](http://www.earumpharma.com)

---

Date: 14<sup>th</sup> February, 2024

To,  
**BSE Limited**  
Phiroze Jeejeebhoy Tower,  
Dalal Street,  
Mumbai – 400 001

Dear Sir/ Madam,

**Sub: Submission of Unaudited Financial Results for the Quarter and Nine Months ended on 31<sup>st</sup> December, 2023 along with Limited Review Report**

**Ref: Security Id: EARUM / Code: 542724**

In reference to captioned subject and pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the Unaudited Financial Results for the Quarter and Nine Months ended on 31<sup>st</sup> December, 2023 along with Limited Review Report.

Kindly take the same on your record and oblige us.

Thanking You

**For, Murae Organisor Limited**  
(Formerly known as Earum Pharmaceuticals Limited)

**Manthan Tilva**  
**Managing Director**  
**DIN: 10453462**

# MURAE ORGANISOR LIMITED

*(formally know as Earum Pharmaceuticals Ltd)*

CIN: L24230GJ2012PLC071299

Statement of Standalone Unaudited Financial Results for the quarter and nine months ended December 31, 2023

| (Rs. in Lakh)   |               |                |               |                  |                 |                    |
|---|---------------|----------------|---------------|------------------|-----------------|--------------------|
| Particulars   | Quarter Ended |                |               | Nine Month Ended |                 | For The Year Ended |
|   | 31-12-2023    | 30-09-2023     | 31-12-2022    | 31-12-2023       | 31-12-2022      | 31-03-2023         |
| A Date of start of reporting period   | 01-10-2023    | 01-07-2023     | 01-10-2022    | 01-04-2023       | 01-04-2022      | 01-04-2022         |
| B Date of end of reporting period   | 31-12-2023    | 30-09-2023     | 31-12-2022    | 31-12-2023       | 31-12-2022      | 31-03-2023         |
| C Whether results are audited or unaudited  | Unaudited     | Unaudited      | Unaudited     | Unaudited        | Unaudited       | Audited            |
| <b>1 Revenue From Operations</b>  |               |                |               |                  |                 |                    |
| (a) Revenue From Operations   | 40.16         | 42.86          | 116.66        | 254.33           | 1,255.97        | 1,409.25           |
| (b) Other Income  | (0.00)        | (0.01)         | 139.68        | 65.89            | 226.25          | 226.25             |
| <b>Total Income (a+b)</b>   | <b>40.16</b>  | <b>42.85</b>   | <b>256.34</b> | <b>320.22</b>    | <b>1,482.22</b> | <b>1,635.50</b>    |
| <b>Expenditure</b>  |               |                |               |                  |                 |                    |
| (a) Cost of materials consumed  | -             | -              | -             | -                | -               | -                  |
| (b) Purchases of stock-in-trade   | -             | 56.43          | 132.66        | 213.80           | 1,213.76        | 1,310.68           |
| (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade   | 30.22         | 35.76          | (36.18)       | 138.10           | 56.27           | (88.44)            |
| (d) Employee benefit expense  | 1.20          | 1.61           | 4.03          | 4.97             | 4.51            | 7.61               |
| (e) Finance Costs   | -             | 1.00           | 14.22         | 26.67            | 14.22           | 29.04              |
| (f) Depreciation and amortisation expense   | 1.96          | 1.97           | 2.58          | 5.90             | 7.42            | 10.39              |
| (f) Other Expenses  | 3.13          | 43.93          | 2.13          | 53.00            | 9.17            | 86.70              |
| <b>Total expenses (a to f)</b>  | <b>36.51</b>  | <b>140.70</b>  | <b>119.44</b> | <b>442.44</b>    | <b>1,305.35</b> | <b>1,355.98</b>    |
| <b>Profit (loss) Before exceptional &amp; Extraordinary items and Tax</b>   | <b>3.65</b>   | <b>(97.85)</b> | <b>136.90</b> | <b>(122.22)</b>  | <b>176.87</b>   | <b>279.52</b>      |
| Exceptional items   |               |                |               |                  |                 |                    |
| <b>Profit (loss) from ordinary activities before Extraordinary Items and Tax</b>  | <b>3.65</b>   | <b>(97.85)</b> | <b>136.90</b> | <b>(122.22)</b>  | <b>176.87</b>   | <b>279.52</b>      |
| Extraordinary items   |               |                |               |                  |                 |                    |
| <b>Profit (loss) from ordinary activities before tax</b>  | <b>3.65</b>   | <b>(97.85)</b> | <b>136.90</b> | <b>(122.22)</b>  | <b>176.87</b>   | <b>279.52</b>      |
| Tax Expenses - Current Tax  | -             | (10.74)        | -             | (10.74)          | -               | 81.39              |
| (less):- MAT Credit   | -             | -              | -             | -                | -               | -                  |
| Current Tax Expense Relating to Prior years   | -             | -              | -             | -                | -               | -                  |
| Deferred Tax (Assets)/Liabilities   | -             | -              | -             | -                | -               | -                  |
| <b>Profit (loss) from ordinary activities</b>   | <b>3.65</b>   | <b>(87.11)</b> | <b>136.90</b> | <b>(111.48)</b>  | <b>176.87</b>   | <b>198.13</b>      |
| Profit/(Loss) From Discontinuing Operation Before Tax   | -             | -              | -             | -                | -               | -                  |
| Tax Expenses of Discontinuing Operations  | -             | -              | -             | -                | -               | -                  |
| <b>Net Profit/(Loss) from Discontinuing Operation After Tax</b>   | <b>-</b>      | <b>-</b>       | <b>-</b>      | <b>-</b>         | <b>-</b>        | <b>-</b>           |
| <b>Profit(Loss) For Period Before Minority Interest</b>   | <b>-</b>      | <b>-</b>       | <b>-</b>      | <b>-</b>         | <b>-</b>        | <b>-</b>           |
| Share Of Profit / Loss Associates   |               |                |               |                  |                 |                    |
| Profit/Loss Of Minority Interest  |               |                |               |                  |                 |                    |
| <b>Net Profit (+)/ Loss (-) For the Period</b>  | <b>3.65</b>   | <b>(87.11)</b> | <b>136.90</b> | <b>(111.48)</b>  | <b>176.87</b>   | <b>198.13</b>      |
| <b>Other Comprehensive Income (OCI)</b>   | <b>-</b>      | <b>-</b>       | <b>-</b>      | <b>-</b>         | <b>-</b>        | <b>-</b>           |
| A. Items that will not be reclassified to profit and loss (Net of tax)  |               |                |               |                  |                 |                    |
| B. Items that will be reclassified to profit and loss (Net of tax)  |               |                |               |                  |                 |                    |
| <b>Total Comprehensive Income for the period comprising Profit/( loss) and other comprehensive income for the period</b>              | <b>3.65</b>   | <b>(87.11)</b> | <b>136.90</b> | <b>(111.48)</b>  | <b>176.87</b>   | <b>198.13</b>      |
| <b>Details of equity share capital</b>  |               |                |               |                  |                 |                    |
| Paid-up equity share capital  | 4,942.23      | 4,942.23       | 1,233.58      | 4,942.23         | 1,233.58        | 1,233.58           |
| Face value of equity share capital (per share)  | 2.00          | 2.00           | 2.00          | 2.00             | 2.00            | 2.00               |
| <b>Details Of Debt Securities</b>   |               |                |               |                  |                 |                    |
| Paid-up Debt Capital  | -             | -              | -             | -                | -               | -                  |
| Face value of Debt Securities   | -             | -              | -             | -                | -               | -                  |
| Other Equity (excluding Revaluation Reserve)  | -             | -              | -             | -                | -               | -                  |
| Debentuer Redemption Reserve  | -             | -              | -             | -                | -               | -                  |
| <b>Earnings per share (EPS)</b>   |               |                |               |                  |                 |                    |
| <b>Earnings per equity share ( For continuing operations)(EPS for the Quarter and nine months not annualised):</b>                    |               |                |               |                  |                 |                    |
|   | 0.00          | (0.04)         | 0.19          | (0.05)           | 0.25            | 0.28               |
|   | 0.00          | (0.04)         | 0.19          | (0.05)           | 0.25            | 0.28               |
| <b>Earnings per equity share (For discontinued operations)</b>  |               |                |               |                  |                 |                    |
|   | -             | -              | -             | -                | -               | -                  |
|   | -             | -              | -             | -                | -               | -                  |
| <b>Earnings per equity share ( For discontinued &amp; continuing operations)(EPS for the Quarter and nine months not annualised):</b> |               |                |               |                  |                 |                    |
|   | 0.00          | (0.04)         | 0.19          | (0.05)           | 0.25            | 0.28               |
|   | 0.00          | (0.04)         | 0.19          | (0.05)           | 0.25            | 0.28               |

**Notes:-**

- 1 These standalone unaudited financial results of the Company for the quarter and nine months ended 31st December, 2023 have been reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on 14th February, 2024. The Statutory Auditors of the Company have conducted a limited review of these financial results.
- 2 The above standalone unaudited financial results have been prepared in accordance with the recognition and measurement principles of the Companies Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended thereafter and other recognized accounting practices and policies to the extent applicable.
- 3 These results have been prepared in accordance with the Indian Accounting Standard (referred to as "Ind AS") 34 - Interim Financial Reporting.
- 4 The Company has one single segment i.e. Pharmaceuticals Trading Hence, separate information for segment wise disclosure is given in accordance with the requirements of Ind AS (AS) 108 - "Segment Reporting" is not required.
- 5 During the year company has issued the 24,67,16,400 right share at price of Rs. 2/- per share. The effect of right issue has been incorporate in the EPS of pervious year as per the Ind AS 33 "Earning per shares" and restated the same.
- 6 The figures for the corresponding previous period have been regrouped/ reclassified wherever necessary, to make them comparable.

For, Murae Organisor Limited  
(formally know as Earum Pharmaceuticals Ltd)

Date :- 14-02-2024  
Place :- Ahmedabad

Manthan Tilva  
Managing Director  
DIN: 10453462




**Independent Auditor's Review Report on the Quarterly and year to date Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended)**

Review Report to  
The Board of Directors  
Murae Organisor Limited  
(Formerly known as Earum Pharmaceuticals Limited)

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Murae Organisor Limited (Formerly known as Earum Pharmaceuticals Limited)** ("the Company") for the quarter and nine months ended December 31, 2023 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with the applicable Indian Accounting Standards ('IND AS') prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material mis-statement.

For, D G M S & Co.  
Chartered Accountants

  
Shashank P. Doshi  
Partner  
Membership No. 108456  
FRN: 0112287W  
Date: 14-02-2024  
Place: Jamnagar  
UDIN: 24108456BKAVD05538

**Head Office :** 217/218/219, Manek Center, P.N. Marg, Jamnagar - 361008.  
**Cell:** 91 98242 31214 **Ph.:** 0288 2661942 **Email:** dgmsco.jam@gmail.com  
**Branch Office :** Shop No. F-04A, 1st Floor, Eternity Mall, Naupada, Teen Haath Naka, LBS Marg, Eastern Express Highway, Thane West - 400604.